pediatrix(US:MD)2025-11-03 11:50Revenue Performance - Pediatrix reported net revenue of $492.9 million for Q3 2025, a decrease from $511.2 million in Q3 2024, reflecting a non-same unit activity impact[2] - Net revenue for Q3 2025 was $492.9 million, a decrease of 3.5% from $511.2 million in Q3 2024[25] - For the nine months ended September 30, 2025, Pediatrix generated revenue of $1.42 billion, down from $1.51 billion in the prior-year period[14] Income and Earnings - The company achieved a net income of $72 million, or $0.84 per diluted share, compared to $19.4 million, or $0.23 per diluted share, in the prior-year period[12] - Net income for Q3 2025 was $71.7 million, compared to $19.4 million in Q3 2024, representing a significant increase[25] - For the nine months ended September 30, 2025, net income was $131.7 million, a turnaround from a loss of $129.5 million in the same period of 2024[30] Adjusted EBITDA - Adjusted EBITDA for Q3 2025 was $87.3 million, up from $60.2 million in Q3 2024, driven by favorable same-unit results and practice disposition activity[9] - Adjusted EBITDA for Q3 2025 was $87.3 million, up 45% from $60.2 million in Q3 2024[27] - The company raised its full-year 2025 Adjusted EBITDA outlook to a range of $270 million to $290 million[18] - The company expects adjusted EBITDA for the year ending December 31, 2025, to be in the range of $270 million to $290 million[34] Cash Flow and Liquidity - Cash from operating activities for Q3 2025 was $138.1 million, compared to $95.7 million in Q3 2024[16] - Cash and cash equivalents increased to $340.1 million from $229.9 million at the end of 2024, reflecting improved liquidity[32] Debt and Liabilities - Total debt outstanding as of September 30, 2025, was $602 million, with no outstanding borrowings under its $450 million revolving line of credit[17] - Total liabilities decreased to $1.3 billion from $1.39 billion at the end of 2024, indicating a reduction in financial obligations[32] Expenses - General and administrative expenses increased to $60.8 million in Q3 2025 from $58.1 million in Q3 2024, primarily due to higher incentive compensation[7] - Operating expenses totaled $424.8 million in Q3 2025, down 11% from $477.3 million in Q3 2024[25] Investments - The company recognized a net gain on investments in divested businesses of $20.9 million during Q3 2025[12] Assets - Total assets as of September 30, 2025, were $2.2 billion, an increase from $2.15 billion as of December 31, 2024[32]